Drug development

#Cancer research #Drug development #Therapeutics

Vivan Therapeutics joins global Repositive Cancer Model network

Repositive has announced that UK-based personalised therapeutics company Vivan Therapeutics will join its network of cancer model partners. Vivan Therapeutics is a personalised therapeutics company that engineers drosophila ‘avatar’ models for cancer research and development. Its technology engineers the genetic complexity of a cancer patient’s unique tumour network (up to… Read More

#Cancer Research #News

#Drug development #Drug discovery #Gene therapy #Therapeutics

Geneticist launches Axovia Therapeutics to develop medicines for ciliopathies

Axovia Therapeutics, a gene therapy company developing disease-transformative medicines for ciliopathies, led by researcher Professor Philip Beales, has launched after being in stealth mode for the past year. Axovia is a majority-owned subsidiary of Jaguar Gene Therapy, and is partially funded by UCL Technology Fund. Axovia is receiving initial operational… Read More

#Editor's Choice #News

#Diagnostics #Drug development #Drug discovery #Webinar

Why hepatocytes are enabling antimalarial drug discovery

BioIVT, providers of research models and services for drug and diagnostic development, will be hosting a webinar where researchers from the University of Georgia will explain the first medium-throughput, 384-well plate-based liver-stage antimalarial drug discovery platform which they have developed. The webinar, entitled Identifying the Critical Factors Enabling a Phenotypic… Read More

#News

#Coronavirus #Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Pandemic #Sitting Down With #Therapeutics

How critical is the part therapeutics have to play in the pandemic?

This DDW Sponsored Sitting Down With episode features Guy Goldberg, Chief Business Officer of RedHill Biopharma. In this episode  – Guy Goldberg discusses COVID-19 therapeutics and their role in the pandemic. Goldberg shares his market insight, the benefits of an orally-administered small molecule tablet for COVID treatment and how the… Read More

#Podcasts

#Biotechnology #Coronavirus #Covid-19 #Drug development #Drug discovery #Metabolomics #Metabolon #Narrated podcasts #Pharmaceutical

The potential of metabolomics & COVID-19 Vaccine Development

Today’s episode is titled The potential of metabolomics & COVID-19 Vaccine Development, and covers 2 articles taken from the most recent Fall issue of DDW. These articles are titled: Why metabolomics has the potential to transform diagnosis and treatment. & COVID-19 Vaccine Development: dethroning evil King Coronavirus These articles were firstly… Read More

#Podcasts

#Biotechnology #Drug development #Drug discovery

Quotient Sciences CEO talks acquisitions, efficiency and finding cures fast

Mark Egerton, Chief Executive Officer, Quotient Sciences, spoke to Lu Rahman about the company’s acquisition of Arcinova and what it means for the drug discovery sector. Quotient Sciences, the drug development and manufacturing accelerator, recently acquired Arcinova, the UK-based multiservice contract development and manufacturing organisation (CDMO). Boasting over 40 years of… Read More

#Editor's Choice #News #Trending News

#Biotechnology #Clinical trials #Drug development #Pharmaceutical

New psychedelic medicine COO looks to boost pharma and biotech collaborations

Beckley Psytech, a company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has appointed Andy Page as its Chief Operating Officer. Page brings over 25 years’ experience working within global pharmaceutical and medtech organisations in strategic and operation roles. He started his career at SmithKline Beecham before joining… Read More

#Editor's Choice #News

#Clinical trials #CRO #Drug development

New partnership uses data to help drug developers with patient recruitment

Cerba Research, a healthcare diagnostic company, has formed a partnership with Biokortex, provider of digital solutions to the healthcare sector. This partnership will leverage patient biological and medical data to support drug developers and CROs with patient identification and recruitment activity. “Cerba Healthcare and Cerba Research are committed to investing… Read More

#Editor's Choice #News

#Covid-19 #Diagnostics #Drug development

BioIVT unveils COVID-19 panel to boost vaccine-generated immune response research

BioIVT, provider of research models and services for drug and diagnostic development, has introduced its COVID-19 Vaccination Panel, composed of pre- and post-vaccination serum or PBMC samples, to enable researchers to study blood donors’ vaccine-generated immune response. BioIVT has been providing more than 300 clients with biospecimens to support the… Read More

#Covid-19 #Editor's Choice #News

#CDMO #Drug development

Quotient Sciences acquires Arcinova, a UK CDMO

Quotient Sciences, the drug development and manufacturing accelerator, has acquired Arcinova, the UK-based multiservice contract development and manufacturing organisation (CDMO). With over 40 years of experience and 160 employees, Arcinova provides drug substance, drug product and bioanalysis services to over 200 pharma and biotech customers worldwide. The acquisition expands Quotient’s… Read More

#News

#AI / data analytics / healthtech / informatics #Drug development #Drug discovery #Gene therapy #Life sciences #Narrated podcasts #Stem cells

The power of precision and the potential of human tissue chips

Today’s episode is titled: The power of precision and the potential of human tissue chips, and covers 2 articles taken from the most recent issue of DDW. These articles are titled: The power of precision to keep biologics effective and safe & Why we should be interested in human tissue chips These… Read More

#Podcasts

#Biomarkers #Drug candidates #Drug development #Drug discovery #Hits #Target validation

Evotec and Related Sciences form drug discovery and development partnership

Evotec has entered into an integrated multi-target drug discovery agreement with biotech venture creation firm Related Sciences to generate multiple drug development candidates, biomarkers, and IND filings over a multi-year period. Evotec and Related Sciences will jointly discover and develop a range of therapeutic approaches for clearly defined patient populations… Read More

#Editor's Choice #News

#AI / data analytics / healthtech / informatics #Business #Drug development #Drug discovery #Narrated podcasts

The Business Side of Drug Discovery

Today’s episode on the topic of The Business Side of Drug Discovery, covers 3 articles taken from the most recent Fall issue of DDW. These articles are titled: Building the foundations for post COVID-19 R&D, Opportunity Knocks: Why compound screening libraries are worth the investment, and How to achieve data driven R&D at speed… Read More

#Podcasts

#Drug development #Immunology / Virology & Vaccines

Why Nexelis is ‘changing the R&D paradigm in vaccines’

Benoit Bouche, President and CEO, Nexelis, told Lu Rahman about the company’s recent acquisition and what it means for the business and the vaccine sector. Nexelis is a leading provider of assay development and advanced laboratory testing services in the infectious diseases, metabolic diseases, and oncology fields. The company –… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#AI #Assay development optimisation & technology #Biologics / Biotechnology #Cancer research #Drug development #Drug discovery #Vaccines

Latest issue of DDW now available

The Winter 2020/21 issue of DDW is now available in print and via the DDW App, featuring the latest innovation and insight from the drug discovery and development community. This season’s issue contains features on vaccines and immunology, AI and the US biotech sector plus expertise from companies such as… Read More

#Editor's Choice #News

#AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Drug development #Drug discovery #Narrated podcasts #Research

Innovation and Opportunity in Drug Discovery

Today’s episode on the topic of Innovation and Opportunity in Drug Discovery, covers 3 articles taken from the most recent Fall issue of DDW. These articles are titled: Japanese drug development: Where is the innovation, Where are the opportunities in global drug discovery, and New for Old: The value behind drug repurposing. These… Read More

#Podcasts